Moteur de recherche d’entreprises européennes
Financement de l’UE (5 998 786 €) : Essai sur la prévention secondaire de la maladie cardiovasculaire chez les personnes âgées Hor 01/05/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Essai sur la prévention secondaire de la maladie cardiovasculaire chez les personnes âgées
While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population (≥ 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.
| Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) | 1 465 972 € |
| Charite - Universitaetsmedizin Berlin | 1 096 546 € |
| CHU de Besancon | 232 609 € |
| Ferrer Internacional SA | 263 574 € |
| Fundacion para La Investigacion Biomedica del Hospital Universitario Clinico San Carlos | 0,00 € |
| Istituto Di Ricerche Farmacologiche Mario Negri | 1 034 363 € |
| London School of Hygiene and Tropical Medicine Royal Charter | 104 259 € |
| PNO Innovation | 391 513 € |
| Semmelweis Egyetem | 184 650 € |
| Servicio Madrileno de Salud | 794 166 € |
| Uniwersytet Medyczny im Piastow Slaskich WE Wroclawiu | 211 251 € |
| Vseobecna Fakultni Nemocnice V Praze | 219 884 € |
https://cordis.europa.eu/project/id/633765
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.